 | Up a level |
Demetri, G. D., Paz-Ares, L., Farago, A. F., Liu, S. V., Chawla, S. P., Tosi, D., Kim, E. S., Blakely, C., Krauss, J. C., Sigal, D., Bazhenova, L., John, T., Besse, B., Wolf, J., Seto, T., Chow-Maneval, E., Multani, P. S., Johnson, A. D., Simmons, B. and Doebele, R. C. (2018). Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Demetri, G. D., Paz-Ares, L., Farago, A. F., Liu, S. V., Chawla, S. P., Tosi, D., Kim, E. S., Blakely, C. M., Krauss, J. C., Sigal, D., Bazhenova, L., John, T., Besse, B., Wolf, J., Seto, T., Chow-Maneval, E., Multani, P. S., Johnson, A., Simmons, B. and Doebele, R. C. (2018). Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001. Ann. Oncol., 29. S. 175 - 176. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Doebele, R., Ahn, M., Siena, S., Drilon, A., Krebs, M., Lin, C., De Braud, F., John, T., Tan, D., Seto, T., Dziadziuszko, R., Arkenau, H., Barlesi, F., Rolfo, C., Wolf, J., Chow-Maneval, E., Multani, P., Cui, N., Riehl, T. and Cho, B. C. (2018). Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC). J. Thorac. Oncol., 13 (10). S. S321 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380
Drilon, A., Paz-Ares, L., Doebele, R. C., Farago, A. F., Liu, S. V., Chawla, S. P., Tosi, D., Blakely, C. M., Krauss, J. C., Bazhenova, L., John, T., Besse, B., Wolf, J., Seto, T., Cho, B. C., Rolfo, C., Osborne, S., Aziez, A. and Demetri, G. D. (2020). Entrectinib in NTRK fusion-positive NSCLC: Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Ann. Oncol., 31. S. S474 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Dziadziuszko, R., Siena, S., Tan, D. S. W., Cho, B. C., Ahn, M-J., Goto, K., Garrido-Lopez, P., Farago, A. F., Loong, H. H. F., Tosi, D., John, T., Wolf, J., Chiu, C-H., Liu, S. V., Patel, M. R., Drilon, A., Pitcher, B., Simmons, B. and Doebele, R. C. (2020). Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline. Ann. Oncol., 31. S. S833 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Passaro, A., Leighl, N., Blackhall, F., Popat, S., Kerr, K., Ahn, M. J., Arcila, M. E., Arrieta, O., Planchard, D., de Marinis, F., Dingemans, A. M., Dziadziuszko, R., Faivre-Finn, C., Feldman, J., Felip, E., Curigliano, G., Herbst, R., Janne, P. A., John, T., Mitsudomi, T., Mok, T., Normanno, N., Paz-Ares, L., Ramalingam, S., Sequist, L., Vansteenkiste, J., Wistuba, I. I., Wolf, J., Wu, Y. L., Yang, S. R., Yang, J. C. H., Yatabe, Y., Pentheroudakis, G. and Peters, S. (2022). ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann. Oncol., 33 (5). S. 466 - 488. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Paz-Ares, L., Doebel, R. C., Farago, A. F., Liu, S., Chawla, S. P., Tosi, D., Blakely, C. M., Krauss, J. C., Sigal, D., Bazhenova, L., John, T., Besse, B., Wolf, J., Seto, T., Chow-Maneval, E., Ye, C., Simmons, B. and Demetri, G. D. (2020). Entrectinib in neurotrophic receptor tyrosine kinase fusion-positive (NTRK-fp) non-small cell lung cancer (NSCLC): integrated analysis of patients enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001. Pneumologie, 74. S. S128 - 2. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790